2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Surgical Wound Infection
5
Neoplasms
4
Colorectal Neoplasms
4
Sepsis
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Leukemia, Myeloid, Acute
2
Febrile Neutropenia
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solitary Pulmonary Nodule
1
Skin Neoplasms
1
Pancreatic Fistula
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Multiple Pulmonary Nodules
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Inflammation
1
Infections
1
Hematologic Neoplasms
1
Glioblastoma
1
Fever
1
Exanthema
1
Emergencies
1
Interventions
Gemcitabine
95
Cisplatin
72
Capecitabine
39
Oxaliplatin
38
durvalumab
29
Fluorouracil
27
pembrolizumab
26
Leucovorin
23
S 1 (combination)
19
Nivolumab
14
Irinotecan
14
lenvatinib
13
Bevacizumab
13
tremelimumab
10
130-nm albumin-bound paclitaxel
9
apatinib
8
Trastuzumab
7
Injections
7
Immune Checkpoint Inhibitors
7
Docetaxel
7
Albumin-Bound Paclitaxel
7
Paclitaxel
6
Drug Therapy
6
titanium silicide
5
surufatinib
5
irinotecan sucrosofate
5
gemcitabine-oxaliplatin regimen
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Anti-Bacterial Agents
×
Clear all
NCT03631173
2026-04-28
MINIMUM
Oslo University Hospital
Phase NA
Active not recruiting
201 enrolled